IRONWOOD PHARMACEUTICALS INC (IRWD) Stock Fundamental Analysis

NASDAQ:IRWD • US46333X1081

3.66 USD
+0.3 (+8.93%)
At close: Feb 26, 2026
3.7 USD
+0.04 (+1.09%)
After Hours: 2/26/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to IRWD. IRWD was compared to 521 industry peers in the Biotechnology industry. IRWD has only an average score on both its financial health and profitability. IRWD has a bad growth rate and is valued cheaply.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year IRWD was profitable.
  • In the past year IRWD had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: IRWD reported negative net income in multiple years.
  • IRWD had a positive operating cash flow in 4 of the past 5 years.
IRWD Yearly Net Income VS EBIT VS OCF VS FCFIRWD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B

1.2 Ratios

  • IRWD has a better Return On Assets (7.21%) than 92.51% of its industry peers.
  • IRWD's Return On Invested Capital of 73.91% is amongst the best of the industry. IRWD outperforms 99.81% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for IRWD is significantly above the industry average of 18.14%.
  • The last Return On Invested Capital (73.91%) for IRWD is above the 3 year average (36.95%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.21%
ROE N/A
ROIC 73.91%
ROA(3y)-65.53%
ROA(5y)-26.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)36.95%
ROIC(5y)30.66%
IRWD Yearly ROA, ROE, ROICIRWD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

  • IRWD's Profit Margin of 8.42% is amongst the best of the industry. IRWD outperforms 90.02% of its industry peers.
  • In the last couple of years the Profit Margin of IRWD has declined.
  • IRWD's Operating Margin of 42.38% is amongst the best of the industry. IRWD outperforms 99.04% of its industry peers.
  • In the last couple of years the Operating Margin of IRWD has remained more or less at the same level.
Industry RankSector Rank
OM 42.38%
PM (TTM) 8.42%
GM N/A
OM growth 3Y-21.4%
OM growth 5Y0.07%
PM growth 3Y-87.48%
PM growth 5Y-45.09%
GM growth 3YN/A
GM growth 5YN/A
IRWD Yearly Profit, Operating, Gross MarginsIRWD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • IRWD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • There is no outstanding debt for IRWD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IRWD Yearly Shares OutstandingIRWD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
IRWD Yearly Total Debt VS Total AssetsIRWD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of -3.26, we must say that IRWD is in the distress zone and has some risk of bankruptcy.
  • IRWD has a Altman-Z score of -3.26. This is comparable to the rest of the industry: IRWD outperforms 45.87% of its industry peers.
  • The Debt to FCF ratio of IRWD is 8.64, which is on the high side as it means it would take IRWD, 8.64 years of fcf income to pay off all of its debts.
  • IRWD's Debt to FCF ratio of 8.64 is amongst the best of the industry. IRWD outperforms 90.79% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 8.64
Altman-Z -3.26
ROIC/WACC9.36
WACC7.9%
IRWD Yearly LT Debt VS Equity VS FCFIRWD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

2.3 Liquidity

  • A Current Ratio of 1.13 indicates that IRWD should not have too much problems paying its short term obligations.
  • IRWD has a worse Current ratio (1.13) than 85.22% of its industry peers.
  • A Quick Ratio of 1.13 indicates that IRWD should not have too much problems paying its short term obligations.
  • IRWD's Quick ratio of 1.13 is on the low side compared to the rest of the industry. IRWD is outperformed by 84.26% of its industry peers.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 1.13
IRWD Yearly Current Assets VS Current LiabilitesIRWD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 1050.00% over the past year.
  • Measured over the past years, IRWD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -21.87% on average per year.
EPS 1Y (TTM)1050%
EPS 3Y-38.11%
EPS 5Y-21.87%
EPS Q2Q%-150%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-47.31%

3.2 Future

  • Based on estimates for the next years, IRWD will show a very negative growth in Earnings Per Share. The EPS will decrease by -15.01% on average per year.
  • IRWD is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -10.69% yearly.
EPS Next Y254.78%
EPS Next 2Y106.33%
EPS Next 3Y55.63%
EPS Next 5Y-15.01%
Revenue Next Year37.22%
Revenue Next 2Y26.17%
Revenue Next 3Y5.66%
Revenue Next 5Y-10.69%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
IRWD Yearly Revenue VS EstimatesIRWD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
IRWD Yearly EPS VS EstimatesIRWD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 15.91, IRWD is valued correctly.
  • IRWD's Price/Earnings ratio is rather cheap when compared to the industry. IRWD is cheaper than 96.16% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.21, IRWD is valued a bit cheaper.
  • With a Price/Forward Earnings ratio of 4.49, the valuation of IRWD can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, IRWD is valued cheaply inside the industry as 98.85% of the companies are valued more expensively.
  • IRWD is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 15.91
Fwd PE 4.49
IRWD Price Earnings VS Forward Price EarningsIRWD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 98.46% of the companies in the same industry are more expensive than IRWD, based on the Enterprise Value to EBITDA ratio.
  • 99.23% of the companies in the same industry are more expensive than IRWD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 8.8
EV/EBITDA 6.81
IRWD Per share dataIRWD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • IRWD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of IRWD may justify a higher PE ratio.
  • A more expensive valuation may be justified as IRWD's earnings are expected to grow with 55.63% in the coming years.
PEG (NY)0.06
PEG (5Y)N/A
EPS Next 2Y106.33%
EPS Next 3Y55.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • IRWD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IRONWOOD PHARMACEUTICALS INC

NASDAQ:IRWD (2/26/2026, 8:00:02 PM)

After market: 3.7 +0.04 (+1.09%)

3.66

+0.3 (+8.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners93.44%
Inst Owner Change2.09%
Ins Owners2.66%
Ins Owner Change-0.21%
Market Cap595.41M
Revenue(TTM)N/A
Net Income(TTM)28.55M
Analysts78
Price Target4.95 (35.25%)
Short Float %5.99%
Short Ratio2.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)189.22%
Min EPS beat(2)135.29%
Max EPS beat(2)243.14%
EPS beat(4)2
Avg EPS beat(4)27.35%
Min EPS beat(4)-194.1%
Max EPS beat(4)243.14%
EPS beat(8)2
Avg EPS beat(8)-35.16%
EPS beat(12)4
Avg EPS beat(12)-25.25%
EPS beat(16)5
Avg EPS beat(16)-23.37%
Revenue beat(2)2
Avg Revenue beat(2)48.85%
Min Revenue beat(2)37.5%
Max Revenue beat(2)60.19%
Revenue beat(4)2
Avg Revenue beat(4)20.01%
Min Revenue beat(4)-12.28%
Max Revenue beat(4)60.19%
Revenue beat(8)2
Avg Revenue beat(8)4.05%
Revenue beat(12)4
Avg Revenue beat(12)2.43%
Revenue beat(16)6
Avg Revenue beat(16)1.53%
PT rev (1m)0%
PT rev (3m)169.44%
EPS NQ rev (1m)-75%
EPS NQ rev (3m)-89.66%
EPS NY rev (1m)0%
EPS NY rev (3m)19.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-25.4%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.71%
Valuation
Industry RankSector Rank
PE 15.91
Fwd PE 4.49
P/S 1.76
P/FCF 8.8
P/OCF 8.8
P/B N/A
P/tB N/A
EV/EBITDA 6.81
EPS(TTM)0.23
EY6.28%
EPS(NY)0.82
Fwd EY22.3%
FCF(TTM)0.42
FCFY11.36%
OCF(TTM)0.42
OCFY11.37%
SpS2.08
BVpS-1.62
TBVpS-1.64
PEG (NY)0.06
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 7.21%
ROE N/A
ROCE 93.56%
ROIC 73.91%
ROICexc 862.99%
ROICexgc 1040.81%
OM 42.38%
PM (TTM) 8.42%
GM N/A
FCFM 19.96%
ROA(3y)-65.53%
ROA(5y)-26.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)36.95%
ROIC(5y)30.66%
ROICexc(3y)70.13%
ROICexc(5y)67.75%
ROICexgc(3y)71.88%
ROICexgc(5y)68.8%
ROCE(3y)46.77%
ROCE(5y)38.81%
ROICexgc growth 3Y-13.6%
ROICexgc growth 5Y-7.25%
ROICexc growth 3Y-13.97%
ROICexc growth 5Y-7.41%
OM growth 3Y-21.4%
OM growth 5Y0.07%
PM growth 3Y-87.48%
PM growth 5Y-45.09%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 8.64
Debt/EBITDA 2.64
Cap/Depr 1.84%
Cap/Sales 0.01%
Interest Coverage 250
Cash Conversion 46.49%
Profit Quality 236.95%
Current Ratio 1.13
Quick Ratio 1.13
Altman-Z -3.26
F-Score6
WACC7.9%
ROIC/WACC9.36
Cap/Depr(3y)21726.6%
Cap/Depr(5y)13049.4%
Cap/Sales(3y)77.3%
Cap/Sales(5y)46.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1050%
EPS 3Y-38.11%
EPS 5Y-21.87%
EPS Q2Q%-150%
EPS Next Y254.78%
EPS Next 2Y106.33%
EPS Next 3Y55.63%
EPS Next 5Y-15.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-47.31%
Revenue Next Year37.22%
Revenue Next 2Y26.17%
Revenue Next 3Y5.66%
Revenue Next 5Y-10.69%
EBIT growth 1Y33.82%
EBIT growth 3Y-25.57%
EBIT growth 5Y-3.82%
EBIT Next Year69.33%
EBIT Next 3Y56.63%
EBIT Next 5Y12.2%
FCF growth 1Y108.51%
FCF growth 3Y-26.61%
FCF growth 5Y96.83%
OCF growth 1Y-70.15%
OCF growth 3Y-26.6%
OCF growth 5Y57.45%

IRONWOOD PHARMACEUTICALS INC / IRWD FAQ

What is the fundamental rating for IRWD stock?

ChartMill assigns a fundamental rating of 5 / 10 to IRWD.


Can you provide the valuation status for IRONWOOD PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 9 / 10 to IRONWOOD PHARMACEUTICALS INC (IRWD). This can be considered as Undervalued.


Can you provide the profitability details for IRONWOOD PHARMACEUTICALS INC?

IRONWOOD PHARMACEUTICALS INC (IRWD) has a profitability rating of 6 / 10.


What is the earnings growth outlook for IRONWOOD PHARMACEUTICALS INC?

The Earnings per Share (EPS) of IRONWOOD PHARMACEUTICALS INC (IRWD) is expected to grow by 254.78% in the next year.